(CGON) CG Oncology Common stock - Ratings and Ratios

CG Oncology, Inc. (NASDAQ:CGON) is a late-stage clinical biopharmaceutical company dedicated to developing innovative treatments for bladder cancer, with a particular focus on bladder-sparing therapies. This approach is crucial as it aims to preserve patients quality of life, addressing a significant need in current treatment options.

Their pipeline includes several notable candidates. BOND-003 targets high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), a condition where standard treatments often fail, offering new hope. CORE-001 combines cretostimogene with pembrolizumab, a well-known checkpoint inhibitor, for similar high-risk NMIBC patients, while CORE-002 pairs cretostimogene with nivolumab for those with muscle-invasive bladder cancer, exploring combination therapies that could enhance efficacy.

Additionally, PIVOT-006 is being developed as a monotherapy for intermediate-risk NMIBC post-surgery, potentially reducing recurrence rates. CORE-008 addresses high-risk NMIBC, including both BCG-exposed and BCG-naïve patients, broadening the treatment scope. These therapies highlight CG Oncologys commitment to exploring various treatment avenues.

Originally known as Cold Genesys, the company rebranded as CG Oncology in 2020, reflecting its focused mission. Founded in 2010 and headquartered in Irvine, California, CG Oncology operates in the biotechnology sector with a market capitalization of approximately $2.3 billion. Their financial metrics, including a P/B ratio of 4.28 and P/S of 3355.72, provide insight into their market position and valuation.

For more details, visit their website: https://cgoncology.com.